Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333

被引:58
作者
Sevin, AD
DeGruttola, V
Nijhuis, M
Schapiro, JM
Foulkes, AS
Para, MF
Boucher, CAB
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[2] Univ Utrecht Hosp, Utrecht, Netherlands
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[4] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1086/315673
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Use of human immunodeficiency virus (HIV) drug-resistance testing in therapeutic decision making may be aided by understanding the relationship between results of genotypic and drug-susceptibility phenotypic assays. We investigated this relationship by applying 3 different statistical methods - cluster analysis, recursive partitioning, and linear discriminant analysis - to results for 72 patients followed in the Adult AIDS Clinical Trials Group (ACTG) protocol 333, ACTG 333 was a multicenter, randomized trial comparing 2 formulations of saquinavir (SQV) to indinavir (IDV) in patients with extensive hard-gel SQV experience. Data include protease amino acid sequences and 50% inhibitory concentrations for SQV and IDV at baseline, The 3 methods give similar results showing the association of mutations at codons 10, 63, 71, and 90 with in vitro resistance to IDV and SQV, Recursive partitioning is especially useful because it can identify interactions among mutations at different codons and accommodates many types of data as well as missing observations.
引用
收藏
页码:59 / 67
页数:9
相关论文
共 31 条
[1]   SmcHD1, containing a structural-maintenance-of-chromosomes hinge domain, has a critical role in X inactivation [J].
Blewitt, Marnie E. ;
Gendrel, Anne-Valerie ;
Pang, Zhenyi ;
Sparrow, Duncan B. ;
Whitelaw, Nadia ;
Craig, Jeffrey M. ;
Apedaile, Anwyn ;
Hilton, Douglas J. ;
Dunwoodie, Sally L. ;
Brockdorff, Neil ;
Kay, Graham F. ;
Whitelaw, Emma .
NATURE GENETICS, 2008, 40 (05) :663-669
[2]   RAPID AND SIMPLE METHOD FOR PURIFICATION OF NUCLEIC-ACIDS [J].
BOOM, R ;
SOL, CJA ;
SALIMANS, MMM ;
JANSEN, CL ;
WERTHEIMVANDILLEN, PME ;
VANDERNOORDAA, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (03) :495-503
[3]   Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay [J].
Boucher, CAB ;
Keulen, W ;
vanBommel, T ;
Nijhuis, M ;
DeJong, D ;
DeJong, MD ;
Schipper, P ;
Back, NKT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2404-2409
[4]   Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor [J].
Condra, JH ;
Holder, DJ ;
Schleif, WA ;
Blahy, OM ;
Danovich, RM ;
Gabryelski, LJ ;
Graham, DJ ;
Laird, D ;
Quintero, JC ;
Rhodes, A ;
Robbins, HL ;
Roth, E ;
Shivaprakash, M ;
Yang, T ;
Chodakewitz, JA ;
Deutsch, PJ ;
Leavitt, RY ;
Massari, FE ;
Mellors, JW ;
Squires, KE ;
Steigbigel, RT ;
Teppler, H ;
Emini, EA .
JOURNAL OF VIROLOGY, 1996, 70 (12) :8270-8276
[5]   HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy [J].
Craig, C ;
Race, E ;
Sheldon, J ;
Whittaker, L ;
Gilbert, S ;
Moffatt, A ;
Rose, J ;
Dissanayeke, S ;
Chirn, GW ;
Duncan, IB ;
Cammack, N .
AIDS, 1998, 12 (13) :1611-1618
[6]  
DeGruttola V, 2000, ANTIVIR THER, V5, P41
[7]   Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].
Durant, J ;
Clevenbergh, P ;
Halfon, P ;
Delgiudice, P ;
Porsin, S ;
Simonet, P ;
Montagne, N ;
Boucher, CAB ;
Schapiro, JM ;
Dellamonica, P .
LANCET, 1999, 353 (9171) :2195-2199
[8]  
Everitt B., 1993, CLUSTER ANAL
[9]   The use of multiple measurements in taxonomic problems [J].
Fisher, RA .
ANNALS OF EUGENICS, 1936, 7 :179-188
[10]  
GINGERAS T, 1998, 2 INT WORKSH HIV DRU, P38